Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
- Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia - - Additional vocal biomarker data from ongoing open label extension study evaluating...
Mogo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
VANCOUVER, British Columbia - Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) ("Mogo" or the "Company"), a digital wealth and payments business, today announced that Greg Feller, President, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference on...
Modular Medical Announces Conference Call to Discuss FDA Clearance of the MODD1 Insulin Pump
SAN DIEGO, CA / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay...
Modular Medical Announces FDA Clearance of the MODD1 Insulin Pump
MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetesDesigned to be simpler and more affordable to expand access to diabetes technology for previously underserved communitiesCommercial availability expected in early 2025 SAN DIEGO, CA / September 4,...
Zoomd Recognized as Top Mobile Marketing Companies for 2024
VANCOUVER, BC, Sept. 4, 2024 -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing technology (MarTech) user-acquisition and engagement platform, is delighted to announce...
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
CUPERTINO, Calif., Sept. 04, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
InfuSystem to Participate in Lake Street’s 8th Annual Best Ideas Growth (BIG8) Conference September 12, 2024
ROCHESTER HILLS, Mich. - InfuSystem Holdings, Inc. (NYSE American: INFU) ("InfuSystem" or the "Company"), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced...
Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer
DUBLIN, Ireland, Sept. 03, 2024 -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Adrian Donohue as Chief...
PolyPid to Participate in Three Upcoming Fall Investor Conferences
PETACH TIKVA, Israel, Sept. 03, 2024 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will participate in the following three investor...
Zoomd Technologies Reports Second Quarter 2024 Financial Results
Conference call will be held on August 28, 2024 at 11 AM ET VANCOUVER, BC, Aug. 28, 2024 -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly-owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing technology (MarTech)...
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024
CARMEL, Ind., Aug. 27, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical...
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024
CUPERTINO, Calif., Aug. 27, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales
DUBLIN, Ireland, Aug. 26, 2024 -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional...
Transforming the Built Environment with Circular Design Technology
Design is the Key to More Sustainable ProductionARCO, Italy, Aug. 26, 2024 -- Aquafil SpA (ECNLF:OTCQX - ECNL:IM), based in Arco (TN) Italy and a pioneer of the circular economy, today released its second in a series of monographs that illustrate how we can design...
SenesTech Announces Closing of Warrant Exercise for $2.3 Million in Gross Proceeds
PHOENIX, Aug. 23, 2024 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, announced today the closing of an exercise of certain existing...
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal...
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
PONTE VEDRA, Fla., Aug. 22, 2024 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart...
Zoomd to Report Second Quarter 2024 Financial Results
VANCOUVER, BC, Aug. 21, 2024 -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly-owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing technology (MarTech) user-acquisition and engagement platform, announced today that it...
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules
CUPERTINO, Calif., Aug. 21, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director
DUBLIN, Aug. 20, 2024 -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of David Ouston as Biosensor Marketing...
Jewett Cameron Launches In-Store Fence Product Displays
NORTH PLAINS, Ore., Aug. 20, 2024 -- Jewett-Cameron Trading Company Ltd. (NASDAQ: JCTCF) has successfully launched in-store merchandiser displays in major home improvement retailers for their integrated steel framework for wood fences. These displays were successfully...
Published Findings Highlight Tecarfarin’s Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
Analysis features the growing need to evolve anticoagulation therapy beyond warfarin to avoid gastrointestinal bleeding, a significant and common complication for left ventricular assist device (LVAD) patients resulting in expensive hospitalizations Tecarfarin, a...
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
One of the most robust forms of intellectual property protection, a composition of matter patent grants ChromaDex exclusive rights to the disodium salt form of NMNH LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide...
Scientific Industries Reports Second Quarter 2024 Results
STRONG PIPELINE FOR BIOPROCESSING DOTS MPS & TORBAL VIVID PILL COUNTEROPERATIONAL EFFICIENCIES CUT QUARTER AND YTD NET LOSS BY 41% AND 28%NET CASH USED BY OPERATIONS REDUCED BY 33%Investor Call to be held Thursday, August 15th at 11:00 a.m. Eastern Time BOHEMIA,...
Greenfire Resources Announces Q2 2024 Results, Updated 2024 Outlook and Appointment of Chief Operating Officer
Calgary, Alberta--(August 14, 2024) - Greenfire Resources Ltd. (NYSE: GFR) (TSX: GFR) ("Greenfire" or the "Company"), a Calgary-based energy company focused on the production and development of thermal energy resources from the Athabasca region of Alberta, Canada, is...